Johns Hopkins opens a small randomized trial pairing virtual reality with psychotherapy after mild TBI
Johns Hopkins University has launched ReVIVE for mTBI, a Phase 1 randomized study testing whether immersive virtual reality can strengthen recovery in adults with mild traumatic brain injury and co-occurring PTSD symptoms. The trial is recruiting veterans with a history of concussion and persistent trauma-related symptoms, a population in whom emotional dysregulation, hypervigilance, and cognitive inefficiency often overlap and reinforce one another.
The design is intentionally modest in size but clinically pointed. Thirty adults are expected to enroll, all of them between 18 and 55 years old, all with prior U.S. military service, and all already receiving some form of usual care before joining the study. Participants are randomized to either six weekly sessions of virtual reality added to standard care or to standard care alone. Open-label assignment leaves little room for procedural masking, so the trial’s value will rest on whether the intervention can produce measurable symptom change on a validated trauma scale and whether participants can tolerate the headset-based sessions without excess discomfort.
The study is built around a simple but compelling bedside question: can an exposure-based virtual environment help people with brain injury and PTSD symptoms practice regulation skills in a way that feels more immediate and more usable than office-based talk therapy alone?
A headset-based intervention built around regulation, exposure, and functional rehearsal
The experimental arm combines virtual reality with ongoing psychotherapy and medication management. Each session begins with roughly 10 minutes of acclimation, followed by about 30 minutes of immersive activities. The content is designed around mindfulness, breathing, grounding, emotional regulation, and everyday tasks staged in simulated environments that become more complex over time. Oculus Quest hardware anchors the intervention, which is not a gaming exercise but a structured rehabilitation tool intended to engage cognitive control, emotional processing, and functional adaptation at the same time.
In practical terms, the intervention tries to capture something traditional psychotherapy may not always reproduce in the clinic: realistic sensory load. People with PTSD frequently experience symptom spikes when confronted with cues that feel too abrupt, too vivid, or too difficult to modulate. For adults with mild TBI, that challenge can be magnified by attention problems, slowed processing, or impaired executive function. A virtual setting can, in theory, offer graduated exposure while preserving enough therapeutic structure to keep the experience tolerable and repeatable.
The control arm stays on the usual clinical path. Participants continue standard psychotherapy and medication management without receiving the virtual reality sessions, but they still complete the study’s scheduled assessments. Standard psychotherapy is not standardized by the protocol; instead, it remains whatever care the treating clinicians have already put in place. That choice preserves real-world relevance, though it also means the trial will compare the new intervention against variable background care rather than a tightly scripted psychotherapy program.
PTSD severity, hyperarousal, and tolerability sit at the center of the protocol
The primary outcome is change in PTSD symptom severity measured with the Davidson Trauma Scale, a 17-item self-report instrument that captures intrusion, avoidance, and hyperarousal. The protocol places particular emphasis on hyperarousal and hypervigilance, the two domains most likely to interfere with sleep, concentration, interpersonal function, and day-to-day safety. In patients with concussion histories, those symptoms often overlap with irritability, cognitive fatigue, and reduced frustration tolerance, making symptom attribution difficult and treatment selection even harder.
The trial also builds in a practical safety check for VR-specific side effects. Tolerability will be monitored with the Simulator Sickness Questionnaire before and after sessions. For a rehabilitation strategy built around immersive visual and vestibular stimulation, that measure matters because nausea, dizziness, disorientation, and headache can derail adherence before any psychiatric benefit has a chance to emerge. Even a small signal of poor tolerability would matter here, because the intervention depends on repeated exposure rather than a one-time therapeutic encounter.
The choice of eligibility criteria reinforces the study’s focus on a relatively specific clinical group. Participants must have had one or more concussions, must have mild-to-moderate PTSD symptoms within a Davidson Trauma Scale range of 20 to 44, and must already have experience with standard care treatments such as psychiatric medication management or evidence-based psychotherapy. The study excludes people older than 55, patients with severe psychiatric disorders, active substance abuse, unrelated neurologic disease, major cognitive impairment, or physical limitations that would prevent safe participation.
Why this trial matters for veterans living with overlapping brain and trauma symptoms
Mild traumatic brain injury and PTSD often travel together after military service, but the symptom burden does not behave like a single disorder. One patient may present with hypervigilance and insomnia, another with poor concentration and emotional flooding, and another with a blend of avoidance, startle responses, and executive dysfunction. Standard psychotherapy can help, but in some patients the therapeutic target is difficult to reach because the brain injury changes how attention, memory, and emotional regulation are recruited in the room.
A virtual environment may help bridge that gap by making therapeutic rehearsal more concrete. Mindfulness and grounding exercises are easier to practice when a patient can work through them in a controlled but sensory-rich simulation. Cognitive and functional tasks may also expose the patient to the kinds of divided attention and emotional interference that trigger real-world problems, giving therapists a structured way to coach regulation in context rather than in abstraction.
The study’s small size and Phase 1 status limit how far the results can travel. Thirty participants will not establish definitive efficacy, and open-label assignment leaves symptom reporting vulnerable to expectancy effects. The schedule also reaches only to a six-week intervention window, with estimated primary completion in May 2027 and study completion in May 2028, so durable benefit remains outside the protocol’s immediate reach. Still, the design is well matched to its first question: whether a virtual reality adjunct can be delivered safely, tolerated consistently, and linked to clinically meaningful movement on a trauma symptom scale in a difficult-to-treat population.
If the intervention works, the biologic logic is straightforward. Repeated, graded exposure paired with real-time regulation coaching may help reduce hyperarousal, improve emotional control, and lessen the reflexive threat response that keeps PTSD symptoms locked in place after concussion. If it does not, the field will still learn something important about the limits of immersive rehabilitation in a group with layered neurologic and psychiatric injury. The trial is now recruiting in Baltimore, with Johns Hopkins Bayview Medical Center serving as the site, and its next value will come from whether the promised symptom relief appears on the Davidson scale or falls short of the expectations built into the protocol.